Macular Degeneration Treatment Market Surpass $11.4 Billion By 2026 | CAGR 6.6%

Author: Acumen Research and Consulting

The global macular degeneration treatment market size is projected to exceed around USD 11.4 billion by 2026, the market is estimated to grow at 6.6% CAGR during the forecast period. Rising incidence of age-related macular degeneration treatment due to the increased geriatric population is the major factor boosting the growth of the global macular degeneration treatment market.

Additionally, there is rapid transformation in the healthcare sector which gives rise to the introduction of innovative drugs that used in the treatment of age-related macular degeneration (AMD) that causes blindness to the elderly population of age 65 or more. Currently, a research study states that around 13 million people in the U.S are suffering from AMD and is expected to grow as there is rise in geriatric population.Increase in R&D investments by key manufacturers has resulted in introduction of innovative products. Increase in incidence of retinal disorders, rise in the aged population, higher annual cost of therapy, improved health care and infrastructure, introduction of innovative therapies, and also the surge in the number of health awareness programs are expected to drive the global macular degeneration treatment market during the forecast period. Continued burden from manufacturers in mandating the use of Avastin for wet age-related macular degeneration treatment and intrusive administration methods are estimated to hinder the global macular degeneration treatment market in the coming years. However, the developed countries such as U.S, Japan, Canada, Germany, Australia, and France offer vast opportunities to the global macular degeneration treatment market. This is driven by the large number of patient population, rise in percentage of urban population, and high compensation.

Download Report Sample Pages For Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1203 

The global macular degeneration treatment market is segmented into disease indication, drug class, distribution channel, and region. On the basis of disease indication, the global macular degeneration treatment market is segmented into dry age-related macular degeneration treatment, wet age-related macular degeneration treatment, and others. On the basis of drug class, the global macular degeneration treatment market is segmented into anti-vascular endothelial growth factor and others. On the basis of distribution channel, the global macular degeneration treatment market is segmented into ambulatory surgical centers, ophthalmic clinics, and hospitals. On the basis of region the global macular degeneration treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Based on end-user, the global macular degeneration treatment market is segmented into ambulatory surgical centers, ophthalmic clinics, and hospitals. The hospitals segment is estimated to hold major share of the global macular degeneration treatment market. Also, the hospital segment is likely to maintain leading position during the forecast period. Also, the major population mainly visits hospital than the ophthalmic clinic for AMD treatment, as the treatment cost is less in hospitals. An ambulatory surgical centers is a relatively less preferred option for the treatment of AMD. The manufacturers in the global market are focused on offerings drugs that are approved by U.S. FDA. There rise in number of drug approvals in U.S as there is increase in healthcare expenditure and higher adoption of prescription of age-related macular degeneration diseases drugs in United States. Therefore, this factors are expected to boost the growth of macular degeneration treatment market in U.S.

VIEW DETAIL REPORT WITH COMPLETE TOC@ https://www.acumenresearchandconsulting.com/macular-degeneration-treatment-market 

Some of the prominent players in the global macular degeneration treatment market are GlaxoSmithKline plc, Novartis AG, Bayer AG, Neurotech Pharmaceuticals, Inc., Ophthotech Corporation, F. Hoffmann-La Roche Ltd., StemCells Inc., Pfizer, Inc., Sanofi, Santen Pharmaceuticals, Allergan, Inc., and Valeant Pharmaceuticals etc.The key manufacturers in the global macular degeneration treatment market are highly focused on investment on research and development activities with an objective to offer differentiated product portfolio in order to increase their customer base in developing regions. The industry players are strategically focused on product innovation, partnership, acquisition, and strategic agreements in order to gain leadership position in the global macular degeneration treatment market. Also, the rise in AMD disease leads to increase in production of innovative drugs that are required as per treatment. These factors are predicted to offer profitable growth opportunities to the prominent players in the global macular degeneration treatment market to gain maximum share.

INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/1203 

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report - https://www.acumenresearchandconsulting.com/buy-now/0/1203 

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 415